Calcium co-ingestion augments postprandial glucose-dependent insulinotropic peptide(1-42), glucagon-like peptide-1 and insulin concentrations in humans

What Was Tested

This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide).

This study determined whether calcium co-ingestion potentiates postprandial GIP(1-42) and GLP-1 concentrations in humans and the concomitant impact on insulin, appetite sensations and substrate metabolism.

Visual analogue scales were used to determine subjective appetite sensations.

Who Took Part

The age groups tagged for this paper are adults, men only.

Ten healthy males consumed two energy- and macronutrient-matched meals in a double-blind, randomized, crossover design.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind GIP (Gastric Inhibitory Polypeptide) study, the assignments were hidden from both participants and investigators until the end.

In the crossover set-up each of the participants took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

Circulating concentrations of GIP(1-42), GLP-1 and insulin were determined over a 180-min postprandial period, followed by 60 min of exercise.

Rates of energy expenditure and substrate (lipid and carbohydrate) oxidation were estimated using indirect calorimetry.

What Was Measured

The subject headings attached to it are Appetite, Blood Glucose, Calcium, Dietary, Calorimetry, Indirect, Energy Metabolism, Exercise and Fatty Acids, Nonesterified.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of GIP (Gastric Inhibitory Polypeptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (European journal of nutrition), a journal based in Germany.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.